Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(55)

カスタマーフィードバック(12)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 NHTiNG5EgXSxdH;4bYMhSXO|YYm= NXfpRVNvOTBibl2= MlnNO|IhcA>? MorySG1UVw>? M1flc3BwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> MlPiNlQ6ODB6N{O=
HT-29 NWfOUXFuS3m2b4TvfIlkKEG|c3H5 MWqxNEBvVQ>? M{\wdVczKGh? NGq1XWNFVVOR NEPseYdRd3SnboTpZZRmeyCmaXfpeI95cW5vaX7keYNm\CCleYTveI95cWOrdIm= NYrkVos{OjR7MEC4O|M>
HT-29 MnqxR5l1d3SxeHnjJGF{e2G7 NWPZeHpnOTBibl2= MmnpO|IhcA>? MVHEUXNQ M4rIU3BwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NGCzTG0zPDlyMEi3Ny=>
PC3 NG\BR2NMcW6jc3WgRZN{[Xl? NGG5fVcyODBibl2= NHX4coEyKGh? M4XENmROW09? MXvQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?= NHzJO2MzOTl5OE[4Ny=>
PC3 NXvRdohGU2mwYYPlJGF{e2G7 M3H6fFExOCCwTR?= Ml3ENUBp NG\hXmhFVVOR NVryfFRKTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= NF;0PHgzOTl5OE[4Ny=>
PC3 MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYWxVGxwOS53IN88US=> M4C4XFEhcA>? MmPzSG1UVw>? NVjtUYg3UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N MmG1NlE6Pzh4OEO=
HEK293 MVvGeY5kfGmxbjDBd5NigQ>? M4f4OVExOCCwTR?= M2i1UVghcA>? MYXEUXNQ M{HG[WlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= M4HIS|IyPTN7M{Cx
BT-20 MnjTT4lv[XOnIFHzd4F6 NWnJUZNrOjBizszN Mn30SG1UVw>? M1HTVmRw\XNibn;0JIlvcGmkaYSgcXRQWkN{IHTldIVv\GWwdDDwRYtVKFN2N{OgdIhwe3Cqb4L5cIF1cW:w M4qyblIyOzV|NUWx
U937 MUjBcpRq[mGldHXybYFtKEG|c3H5 NFrleFQ2OCEQvF2= NFHPepA1QCCq MnTXSG1UVw>? M1LmNWlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= NWOxRW9[OjFzNEKxNFY>
U937 MXrBcpRq[mGldHXybYFtKEG|c3H5 NWXMfJFkPTBizszN M4HEbFQ5KGh? NW\Nco9iTE2VTx?= NGGzUm5Fd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KE2LUDDwdo91\WmwLXTl[olkcWWwdDDM[Ydqd26nbHzhJJBv\XWvb4DobYxiKEqUM{KtNkBqdiCXOUO3JINmdGy| MkTkNlEyPDJzME[=
U937 NEfXdZBCdnSrYnHjeIVzcWGuIFHzd4F6 NVL6dmxCPTBizszN M{[0[FQ5KGh? NY\6WHdFTE2VTx?= NYP2W4tmTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCHc3Po[ZJq[2irYTDjc4xqKEiEMUCxJIlvKFV7M{egZ4VtdHN? NEe5bJIzOTF2MkGwOi=>
MCF-7 MlXERZV1d3CqYXf5JGF{e2G7 MoXwN|Ahdk1? NYHXcmJEPCCq Ml7RSG1UVw>? NF7iOJJKdmS3Y3XzJIF2fG:yaHHnfS=> MUOyNFAzQDF|NB?=
U87MG NXr2WFd3U2mwYYPlJGF{e2G7 MXuxJO69VQ>? M4qwR|YhcA>? NWX0OlRbTE2VTx?= NXzuT3dKWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36= NIDkV4syQTh2OESwOC=>
U87MG NHv6WYZMcW6jc3WgRZN{[Xl? MUmxJO69VQ>? NFzFWIo3KGh? NHTse|lFVVOR Ml:xVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= MV:xPVg1QDRyNB?=
U87MG NE\wbnpMcW6jc3WgRZN{[Xl? NFHycIwyKM7:TR?= MVi2JIg> Mm\qSG1UVw>? MXfEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MYqxPVg1QDRyNB?=
U87MG NUXkV5c2U2mwYYPlJGF{e2G7 MX[xJO69VQ>? NHTjU|I3KGh? NFvKbZFFVVOR M{D5WWRw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN|cwPDZrIIDoc5NxcG:{eXzheIlwdg>? NW\EfVZ3OTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb M3u1OWF2fG:yaHHnfUBCe3OjeR?= NXXQfpJVOC5{IN88US=> M334[lI1KGh? MWXEUXNQ M3PTUWlv\HWlZYOgZZV1d3CqYXf5 MmLNNVg{QTF7NEm=
COS7 cells expressing EGFP-LC3 MVPBeZRweGijZ4mgRZN{[Xl? M{fXelAvOiEQvF2= MXKyOEBp Mo\wSG1UVw>? NYfGSXZtUW6mdXPld{BifXSxcHjh[5k> NH71TIkyQDN7MUm0PS=>
H4 NWe2dWpCTnWwY4Tpc44hSXO|YYm= NXPtV4d5OC5{IN88US=> MVuyOEBp MUDEUXNQ NFnEUI1KdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{ MYKxPFAzPDV6NB?=
HeLa M1\wbGZ2dmO2aX;uJGF{e2G7 MYKxNFAhdk1? NYDnV2pMOzZiaB?= MUnEUXNQ M2DXXmlv\HWlZYOgSnJDKEt{MEm1VEwhXDJyOUjMMEBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> NWT4[3lXOTd3NkOzPFU>
HeLa MV7GeY5kfGmxbjDBd5NigQ>? MXexNFAhdk1? NXvRfY5FOzZiaB?= M2T3WmROW09? MWnJcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> Mk\WNVc2PjN|OEW=
HeLa NWnuc4cyTnWwY4Tpc44hSXO|YYm= MVGxNFAhdk1? M4LuUlM3KGh? MnnPSG1UVw>? M2HXT2lv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> NEjZfZYyPzV4M{O4OS=>
SYF MW\GeY5kfGmxbjDBd5NigQ>? MYSxNFAhdk1? Mkm3NlQhcA>? MXvEUXNQ MUPJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= MXuxO|U3OzN6NR?=
SYF Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\BRYtuOTByIH7N NWf5ZYM4OjRiaB?= NFPpOmpFVVOR MWnJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiU2nGJINmdGy| MoTFNVc2PjN|OEW=
HEK293T MXnBcpRqfmm{YXygRZN{[Xl? NGjqXpAyKG6P M{PWUlQh\A>? M2XJcWROW09? Mm\PTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2= NWO5OoNkOTd2OEW1NFE>
HEK293T NFjCeWxCdnSrdnnyZYwhSXO|YYm= M4G5UlEhdk1? MmOzOEBl M3z0TGROW09? NHrwNYVKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> M3TIXFE4PDh3NUCx
PBMC NXvsWHJ7TnWwY4Tpc44hSXO|YYm= MnvlNUBvVQ>? MlLFNVQh\A>? NWr5N3pGTE2VTx?= M2f2WXJm\HWlZYOgR2NTPSCmZX7zbZR6 MlPONVc1QDV3MEG=
PBMC MoTHSpVv[3Srb36gRZN{[Xl? NEjaN3UyKG6P MkDSNVQh\A>? M1TESWROW09? NXXWcW9NTG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? M{Hz[FE4PDh3NUCx
HEK293 cells MkL4T4lv[XOnIFHzd4F6 MXq1NEBvVQ>? M2Xs[VQ2KG2rbh?= MWPEUXNQ M4Sx[WlvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1? M37QVFE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MUPGeY5kfGmxbjDBd5NigQ>? NYn4XGZYOTByIH7N NGTEc|Y1KGh? NGXHd3pFVVOR NVv3[G9MUW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? NXLmPHNOOTdzMkiyOlI>
Human mixed lymphocyte MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWG1JI5O NIX0XnlFVVOR NWrpb29OUUN3ME2xMlYhdk1w NInDXpUyPjF6NUi2OS=>
Lewis rat lymph node cells M2rtd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33QZlUh|ryP NI\obFBFVVOR NHLoc3lKSzVyPUKuOkDPxE1? M{SwSFE3OTh3OE[1
cells from the thymus of normal BALB/c mice NFKwTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\MWpNuOTBibl2= NE\XWW84OiCq NYjESJRGTE2VTx?= NXzLW3hWUW6qaXLpeJMhdHmvcHjvdJJwdGmoZYLheIlwdiBqTFHGLUB4cXSqIFnDOVAhd2ZiMzDuUS=> NWTRRohUOTByMkG5OFg>
MRK-nu-1 M1vCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwOES1JJBO NWDqVVh5W0GQR1XS
OCUB-M MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTVwMkSgdG0> MkDFV2FPT0WU
SF539 NG[xVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfXN4RKSzVyPUGxMlYheE1? NFzQfZlUSU6JRWK=
ES4 NUnCXpNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXviU4pmUUN3ME2yNU42KHCP MYjTRW5ITVJ?
RL95-2 M3zUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fFd2lEPTB;MUC3JJBO NIPTPJRUSU6JRWK=
LC-2-ad Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTR{MzDwUS=> MkXSV2FPT0WU
Daudi MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fMVWlEPTB;NEO0JJBO NGrReFBUSU6JRWK=
NTERA-S-cl-D1 M2XhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGxWYw2UUN3ME20OFMheE1? NVHXVIZ6W0GQR1XS
OS-RC-2 M17LZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljUTWM2OD14NUKgdG0> M3HDPHNCVkeHUh?=
VA-ES-BJ NUjPVoZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPpXGZIUUN3ME23NlMheE1? Ml75V2FPT0WU
GR-ST MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3qN5dYUUN3ME24OFYheE1? M1P0Z3NCVkeHUh?=
SW872 Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHTbXZKSzVyPUi0OkBxVQ>? MYTTRW5ITVJ?
NOS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTh5MTDwUS=> MXzTRW5ITVJ?
MC116 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf2PItKSzVyPUm4OUBxVQ>? MnHIV2FPT0WU
NCI-H1355 NITVXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHCfIZiUUN3ME2xMlAyKG6P NXzKZY17W0GQR1XS
RPMI-8226 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwMUmgcm0> MlXSV2FPT0WU
TE-15 NYG2VVVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFwM{[gcm0> NX\jVnBtW0GQR1XS
Ramos-2G6-4C10 M1jvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTDT2R6UUN3ME2xMlQ3KG6P Moi3V2FPT0WU
KU812 NGXueGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwMEGgcm0> NIX1eHNUSU6JRWK=
EW-1 NIDrZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W4U2lEPTB;Mj6xO{BvVQ>? NGLENGdUSU6JRWK=
KS-1 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG2TWM2OD1{LkS1JI5O NHn4PFRUSU6JRWK=
SK-LMS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;TOmlEPTB;Mj60PUBvVQ>? MYLTRW5ITVJ?
TGBC1TKB MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnIeXdZUUN3ME2yMlY6KG6P NFnu[GlUSU6JRWK=
TE-6 MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfNfVlqUUN3ME2yMlc4KG6P NVPC[ZFyW0GQR1XS
ETK-1 MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HYRWlEPTB;Mj64NkBvVQ>? NVuyUm5HW0GQR1XS
BE-13 NGD2bnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:5WZFKSzVyPUKuPVkhdk1? M2\SUHNCVkeHUh?=
A3-KAW MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJwOUmgcm0> MUjTRW5ITVJ?
TE-10 NIPZN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTNwMzDuUS=> MnjjV2FPT0WU
DOHH-2 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vJVGlEPTB;Mz6zOUBvVQ>? NXHZZVFbW0GQR1XS
ES6 Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPYVnZKSzVyPUOuOFMhdk1? MVfTRW5ITVJ?
OPM-2 NULZPYx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHSWnZKSzVyPUSuNVUhdk1? NWnJXos3W0GQR1XS
SH-4 M3nlWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTRwM{Sgcm0> M3TPVnNCVkeHUh?=
NB13 M165N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTRwM{[gcm0> M4flPXNCVkeHUh?=
HUTU-80 NEL0PHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3QTWM2OD12LkSyJI5O M3vzbnNCVkeHUh?=
CCRF-CEM NViwSJJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\yTWM2OD12Lkm0JI5O NFHuepRUSU6JRWK=
TGBC24TKB NEflZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj0[o5KSzVyPUWuOVEhdk1? NUXRZppmW0GQR1XS
697 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHKTJdKSzVyPU[uNlghdk1? MlvVV2FPT0WU
J-RT3-T3-5 NUDNbYFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTGTWM2OD14LkS2JI5O NYXKSFZuW0GQR1XS
KALS-1 NGfnNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7tOnN6UUN3ME22MlU3KG6P NFXmSGtUSU6JRWK=
no-10 NIPCVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXGV2ZKSzVyPUeuNlkhdk1? NHLBeXlUSU6JRWK=
SK-NEP-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjUU|h2UUN3ME24Mlc6KG6P MoPYV2FPT0WU
L-540 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq5RYFKSzVyPUGwMlQzKG6P MV3TRW5ITVJ?
JiyoyeP-2003 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\rbYdKSzVyPUGwMlk1KG6P M2XVSHNCVkeHUh?=
HH MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFzLkO5JI5O MVzTRW5ITVJ?
SR MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPWTWM2OD1zMT60OUBvVQ>? NYLL[JZ7W0GQR1XS
QIMR-WIL NIXsZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:zfmlEPTB;MUGuPFUhdk1? MnXxV2FPT0WU
A4-Fuk NFvJT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF|LkGyJI5O M2L1N3NCVkeHUh?=
CESS MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7VPIlYUUN3ME2xN{4yOyCwTR?= NHjXNmFUSU6JRWK=
KE-37 MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HCdWlEPTB;MU[uNFchdk1? Mn;PV2FPT0WU
SK-UT-1 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDIbnRjUUN3ME2xOk45OSCwTR?= MlX4V2FPT0WU
SIG-M5 MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L1[2lEPTB;MUeuNlUhdk1? M4fkVHNCVkeHUh?=
HT NF3qeodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnZPVkxUUN3ME2xO{43KG6P M4Ll[nNCVkeHUh?=
DEL NXzySlNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\XTWM2OD1zNz65PUBvVQ>? NVLhcHZ4W0GQR1XS
SK-PN-DW MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX70NWJDUUN3ME2yNE4zOyCwTR?= MYTTRW5ITVJ?
RPMI-8402 NI\WZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHYTWM2OD1{MT63O{BvVQ>? NUHuNpdsW0GQR1XS
RPMI-6666 M3vmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrmWYpKSzVyPUK0MlQzKG6P NIGyTXBUSU6JRWK=
NCI-H720 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ3LkSxJI5O M4WxRXNCVkeHUh?=
EW-16 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj0NWFKSzVyPUK2Mlg4KG6P MlrhV2FPT0WU
BL-70 MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJ6LkO4JI5O MoD6V2FPT0WU
SF126 MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nrXGlEPTB;M{CuN|ghdk1? MkPuV2FPT0WU
BC-1 MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjBXVZKSzVyPUOxMlI3KG6P NWPZPW5IW0GQR1XS
MHH-PREB-1 NInhdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH30UGpKSzVyPUOyMlQ1KG6P NIrudVZUSU6JRWK=
A101D MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTNdmM1UUN3ME2zNk43OiCwTR?= NFn4NWtUSU6JRWK=
NMC-G1 MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTN|Lk[3JI5O NHTkO45USU6JRWK=
LB1047-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvKTWM2OD1|ND62PUBvVQ>? MmS1V2FPT0WU
EM-2 Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTN6LkWzJI5O M3\LbnNCVkeHUh?=
COLO-684 M13T[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTN7Lkigcm0> MXHTRW5ITVJ?
Becker NVfsZ3BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO5OWNKSzVyPUSxMlA2KG6P NGDqclVUSU6JRWK=
BL-41 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHrTWM2OD12Mz62OkBvVQ>? NF3OdHBUSU6JRWK=
MDA-MB-134-VI MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHMPItCUUN3ME20OE4xOiCwTR?= MUPTRW5ITVJ?
L-363 MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17PS2lEPTB;NESuO|Mhdk1? NHj5cpFUSU6JRWK=
ECC4 Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj5R2JKSzVyPUS0Mlc5KG6P M{HSRnNCVkeHUh?=
A388 NW\6Z5RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3SyZ2lEPTB;NESuPFIhdk1? NYLaZnhjW0GQR1XS
HEL NY\lVYpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjaTWM2OD12OT63PUBvVQ>? NYTrcIpMW0GQR1XS
RKO NFnx[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLVV5hvUUN3ME21NE4zQSCwTR?= MoTBV2FPT0WU
KINGS-1 NVHZb2s1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPZTohmUUN3ME21NU42PSCwTR?= Mnu3V2FPT0WU
EB-3 MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DvOWlEPTB;NUKuOlchdk1? MlTIV2FPT0WU
ARH-77 M4frc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETCPZFKSzVyPUWyMlghdk1? NXW4TVhVW0GQR1XS
GCIY M2XmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf1TWM2OD13Mz60OkBvVQ>? MWLTRW5ITVJ?
NCI-H1304 NUTXTHRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLRV4NKSzVyPUW3MlIzKG6P NHzLU45USU6JRWK=
KARPAS-299 NVL6bJl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HPO2lEPTB;NkGuPFIhdk1? NU\kWZRNW0GQR1XS
IA-LM NFLnNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTZ6LkGzJI5O MV;TRW5ITVJ?
GI-1 MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH4TWM2OD15MD6zPUBvVQ>? NVPXZoRMW0GQR1XS
TE-11 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPLc5A{UUN3ME23O{4yPyCwTR?= MY\TRW5ITVJ?
LS-411N NWXidmtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTd5LkW3JI5O MlKwV2FPT0WU
no-11 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTh|LkK0JI5O NVP5c3hEW0GQR1XS
MV-4-11 M1vs[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL5W5hKSzVyPUizMlc{KG6P MWrTRW5ITVJ?
BV-173 M2PabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTIfmdtUUN3ME24N{46PyCwTR?= NWrjT|NXW0GQR1XS
CMK MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LSd2lEPTB;OESuNVYhdk1? NWLrcJVmW0GQR1XS
LC4-1 Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v5Z2lEPTB;OE[uO|Ihdk1? NInIdlVUSU6JRWK=
COR-L279 MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTh5LkK1JI5O NXTwU|VnW0GQR1XS
NCI-H209 MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTh5LkSxJI5O MmT4V2FPT0WU
Raji MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULCWFV1UUN3ME24PU44OiCwTR?= NWS4R2hDW0GQR1XS
LB996-RCC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy2fGtKSzVyPUmzMlQ{KG6P MX;TRW5ITVJ?
NCI-H526 NXfuZZo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPqTWM2OD17Mz61PUBvVQ>? MXvTRW5ITVJ?
KGN NUi4OW9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTl4LkK5JI5O NG[3d41USU6JRWK=
MOLT-4 Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPJdm1lUUN3ME25Ok44QSCwTR?= NXjaVY4xW0GQR1XS
PF-382 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HhOWlEPTB;OU[uO|khdk1? NFXRXXJUSU6JRWK=
BC-3 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj5UVQ{UUN3ME25PU4yQCCwTR?= Mlm1V2FPT0WU
KARPAS-422 NEPJeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjiOXl2UUN3ME2xNFIvODlibl2= MWnTRW5ITVJ?
SBC-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme5TWM2OD1zMEeuO|Uhdk1? NHu0OXFUSU6JRWK=
LC-1F NEDlZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFyOD6wOUBvVQ>? M{nCRXNCVkeHUh?=
GB-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfKXJRKSzVyPUGwPU4xOiCwTR?= MnPXV2FPT0WU
SNB75 NEfLb2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnOPWZLUUN3ME2xNVkvPjlibl2= MVrTRW5ITVJ?
BB65-RCC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFzOT65N{BvVQ>? MV\TRW5ITVJ?
NCI-N87 NWPhTHZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjXTYZKSzVyPUGyNU46QCCwTR?= NUXQSpBoW0GQR1XS
IST-MEL1 NHf1OohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjuWJpKSzVyPUGyNk4{QCCwTR?= MnzUV2FPT0WU
HOP-62 NFvY[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDnTWM2OD1zMk[uPFkhdk1? MXHTRW5ITVJ?
ACN MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF2Nj63OUBvVQ>? MXHTRW5ITVJ?
DMS-114 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\PTWM2OD1zNUCuOlchdk1? NVfNempVW0GQR1XS
MLMA M3znVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF3OT64PEBvVQ>? Mn;uV2FPT0WU
HT-144 NYnUdHRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF4NT60N{BvVQ>? NVvkXYhmW0GQR1XS
C2BBe1 NGDTT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O1cWlEPTB;MU[3Mlc3KG6P MX7TRW5ITVJ?
L-428 NVT1blk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF5Nz63JI5O MXLTRW5ITVJ?
DU-4475 M1LIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF6Nz62PEBvVQ>? MUfTRW5ITVJ?
CP67-MEL M3rOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF7OT6zPEBvVQ>? MV\TRW5ITVJ?
MEG-01 NYPEbnV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDwO4tKSzVyPUKwNU46PiCwTR?= NH7LeYdUSU6JRWK=
IST-SL2 NGC5RpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jpfWlEPTB;MkC4MlY{KG6P MXXTRW5ITVJ?
ES8 M1HIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS3bXg{UUN3ME2yNlUvQTRibl2= M3zMOXNCVkeHUh?=
COLO-800 MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2i0[mlEPTB;MkO1MlI5KG6P MlfCV2FPT0WU
MFH-ino MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjE[2g3UUN3ME2yN|UvQDRibl2= MmjmV2FPT0WU
OVCAR-4 M2jRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX0N5c{UUN3ME2yN|cvOjRibl2= Mm\kV2FPT0WU
PSN1 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfHc4ZvUUN3ME2yOFIvPzFibl2= M3nRUXNCVkeHUh?=
EW-12 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTiTWM2OD1{NEOuNUBvVQ>? NFPIeYlUSU6JRWK=
HCC1599 NWH4OldRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJ4MT60O{BvVQ>? MXLTRW5ITVJ?
SJSA-1 NYjYUGYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJ5MT60OkBvVQ>? Mn3aV2FPT0WU
ST486 MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJ7Nj6xOEBvVQ>? MV;TRW5ITVJ?
NOMO-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoWxTWM2OD1|MECuNlEhdk1? MUHTRW5ITVJ?
MN-60 MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrKNolsUUN3ME2zNFUvOzJibl2= NUnHZ2loW0GQR1XS
HCC1187 M1qw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi2RYpKSzVyPUOwO{4zPSCwTR?= NE\NS|NUSU6JRWK=
SW982 M37Hdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCwTWM2OD1|MUSuO|Uhdk1? NIPPbohUSU6JRWK=
LB647-SCLC M{\3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHlSmFKSzVyPUOyPE44OSCwTR?= M2L0WXNCVkeHUh?=
HC-1 NXrHZ24{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nzeGlEPTB;M{O1MlUhdk1? NV7uSZU2W0GQR1XS
EHEB NELIPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTN|Nz61NkBvVQ>? M4W5NHNCVkeHUh?=
TUR NHPo[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHTTWM2OD1|NkOuPVUhdk1? MkLJV2FPT0WU
LU-139 NFr2VVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M131ZWlEPTB;M{e4MlAzKG6P MmfyV2FPT0WU
NB1 NVjCOnlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX0fZpKSzVyPUO4OE41PSCwTR?= NEXGbWVUSU6JRWK=
BB30-HNC M4PtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:3R5FKSzVyPUO4PE4{OiCwTR?= NGjRfHVUSU6JRWK=
HAL-01 M3G2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDDZ5RKSzVyPUO4PU4zPiCwTR?= MWnTRW5ITVJ?
K5 M1zhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTRzMT6zO{BvVQ>? NFfne5VUSU6JRWK=
MZ2-MEL NXzSTYtkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fscmlEPTB;NEGzMlY1KG6P NUHKcJg6W0GQR1XS
RXF393 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknYTWM2OD12MU[uOFUhdk1? NILa[XNUSU6JRWK=
NCI-H1648 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXhTWM2OD12MUeuOVMhdk1? Mn20V2FPT0WU
TE-12 M2rqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;0OoRKSzVyPUSzOE4zPiCwTR?= NHTHfYJUSU6JRWK=
EoL-1- NITJeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzPVVJtUUN3ME20N|cvQThibl2= MV;TRW5ITVJ?
JAR M1HQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3foWWlEPTB;NEO4MlYzKG6P NU\nU5JQW0GQR1XS
DSH1 NWDne2NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TldGlEPTB;NEW4MlkyKG6P NV3vS5FEW0GQR1XS
NCI-H187 NFrDTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Hv[GlEPTB;NE[yMlgyKG6P MnHvV2FPT0WU
HCE-4 NHzHbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3tTXg6UUN3ME20O|cvPjZibl2= M3fEPXNCVkeHUh?=
8-MG-BA M1TL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfUSoZlUUN3ME21PFEvPTJibl2= M2jEcnNCVkeHUh?=
KLE MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLqbGNOUUN3ME21PFUvOiCwTR?= MXXTRW5ITVJ?
KNS-42 NHrMZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHrN4VZUUN3ME21PFYvQDFibl2= NHnHfYVUSU6JRWK=
MSTO-211H NHezbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjXUmJ{UUN3ME22NFkvPzRibl2= MXHTRW5ITVJ?
GDM-1 M4DS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlKxTWM2OD14MUSuNFkhdk1? MWrTRW5ITVJ?
TE-1 MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfOVI5KSzVyPU[0Ok4yOiCwTR?= MXfTRW5ITVJ?
BT-474 M2LpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\FU|RTUUN3ME22OFcvODZibl2= M3THR3NCVkeHUh?=
KARPAS-45 MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXHdnhKSzVyPU[0O{43KG6P MojXV2FPT0WU
MOLT-16 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjqTnJbUUN3ME22OFcvQTNibl2= NUnn[ldzW0GQR1XS
KURAMOCHI NYXQN|d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf4TWM2OD14NUeuOVEhdk1? MVPTRW5ITVJ?
K-562 NXzmO5g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi1V3RKSzVyPU[2PU42OSCwTR?= NH\RenhUSU6JRWK=
EKVX NY\6Xpp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:2SoxKSzVyPU[3Nk44OSCwTR?= M2LWcnNCVkeHUh?=
GAK NUP5XJhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq2TWM2OD14N{WuN{BvVQ>? M3L1bXNCVkeHUh?=
NCI-SNU-5 Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPVSGtKSzVyPU[5NE4xOSCwTR?= MVzTRW5ITVJ?
NCI-H2126 M3XwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PCN2lEPTB;N{K2Mlg4KG6P M{nHbXNCVkeHUh?=
CTV-1 NV7uUnJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX5TWM2OD15NESuPUBvVQ>? M4DoVHNCVkeHUh?=
SW962 NFLrdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTd2OD60OEBvVQ>? M4\4WHNCVkeHUh?=
MONO-MAC-6 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTd3Nj65N{BvVQ>? MkDTV2FPT0WU
NCI-H748 M3HweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTd3OD65PUBvVQ>? Mnf4V2FPT0WU
NCI-H524 NUHMXYk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDjbmRKSzVyPUe4NE44OyCwTR?= NFXvSlhUSU6JRWK=
LS-123 NHjBU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX6NIdKSzVyPUe5OU43QSCwTR?= MWDTRW5ITVJ?
NB7 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[3UWlEPTB;OEG0MlE1KG6P MXzTRW5ITVJ?
LS-1034 NH:1VVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXSTWM2OD16MkiuPVghdk1? MlzEV2FPT0WU
TE-5 NYT2ZWppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPiTWM2OD16OEOuOVYhdk1? NYCwPFc6W0GQR1XS
A704 M2rRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUixdlZrUUN3ME24PVkvOTVibl2= NITGXWpUSU6JRWK=
TK10 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;SZmlEPTB;OUG2MlA{KG6P MXrTRW5ITVJ?
NCI-H345 NXTibJRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHp[WhKSzVyPUm0N{4zOiCwTR?= Moj0V2FPT0WU
CGTH-W-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7LW|lXUUN3ME25OFgvOTNibl2= NXjXNJZuW0GQR1XS
NCI-H510A M{\yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPSTWM2OD17OEWuNVIhdk1? MULTRW5ITVJ?
NCI-H1963 NXPDbZFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnmwTWM2OD1zLkCzNlkzKM7:TR?= NEfUe|dUSU6JRWK=
SCC-3 M{TUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\ROodKSzVyPUGuNFM1OTRizszN NE\ZdGNUSU6JRWK=
EW-11 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjVW2tKSzVyPUGuNFg4PDNizszN NU\Mb5Q3W0GQR1XS
CPC-N NV7qXWlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjibnVKSzVyPUGuNFg5KM7:TR?= NEHmc5BUSU6JRWK=
NCI-H1417 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX4TWM2OD1zLkGyNlYh|ryP MYHTRW5ITVJ?
DG-75 M{nXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILGNm5KSzVyPUGuNVYzQDVizszN MXvTRW5ITVJ?
HD-MY-Z MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjsSm9KSzVyPUGuNVY1OTZizszN NGmxNVlUSU6JRWK=
ATN-1 M1jsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLMTWM2OD1zLkK2NlA6KM7:TR?= NFfXT4tUSU6JRWK=
KM-H2 MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkThTWM2OD1zLkK2OFA5KM7:TR?= MnHUV2FPT0WU
NCI-H2081 MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfWNJpKSzVyPUGuNlY3OzdizszN M2f1SnNCVkeHUh?=
HL-60 M{L6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X5T2lEPTB;MT6yOlk2QSEQvF2= M4\M[HNCVkeHUh?=
DB MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon2TWM2OD1zLkK3NlQzKM7:TR?= NF3xZYNUSU6JRWK=
NCI-H1522 NGjEWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrCbGlKSzVyPUGuNlg5QDdizszN M1LrW3NCVkeHUh?=
AM-38 NHn1UY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwM{C3NkDPxE1? NGT3[WtUSU6JRWK=
NCI-H446 Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLUd4lKSzVyPUGuN|IyOjFizszN M3\0TnNCVkeHUh?=
SU-DHL-1 M2OxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwM{K4NFEh|ryP NEfsS|RUSU6JRWK=
NH-12 NGLN[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH1TWM2OD1zLkO2N|c1KM7:TR?= NFL5bYhUSU6JRWK=
DMS-79 MmnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH2wbXVKSzVyPUGuN|Y5PjZizszN MYTTRW5ITVJ?
NCI-H716 NFvzT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;Pd|JKSzVyPUGuN|g6QDZizszN NX3DXYxZW0GQR1XS
ML-2 MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33Z[2lEPTB;MT60NVUzQSEQvF2= Mn;PV2FPT0WU
NB10 M3u1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4KyPWlEPTB;MT60OlY{OiEQvF2= Mnr5V2FPT0WU
ONS-76 M2S4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFwNUO1Olkh|ryP Mn3vV2FPT0WU
LOUCY Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvSbXBOUUN3ME2xMlU1PjV5IN88US=> MknyV2FPT0WU
SCLC-21H MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwNUi1PFIh|ryP NX;mV3BSW0GQR1XS
TGW NIHLWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfnWFFKSzVyPUGuOlM6PzVizszN M13NTXNCVkeHUh?=
LXF-289 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwN{OyOlgh|ryP MUDTRW5ITVJ?
BB49-HNC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGSxOoRKSzVyPUGuO|M2QDZizszN MY\TRW5ITVJ?
NCI-H747 NFL5d5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TOcmlEPTB;MT63OVM1PiEQvF2= NWfyTHRmW0GQR1XS
LU-165 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFwOES5PFYh|ryP M3vEXnNCVkeHUh?=
OMC-1 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfZTWM2OD1zLkm1NFY3KM7:TR?= Mm\sV2FPT0WU
RCC10RGB NHzKeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;WfJNKSzVyPUGuPVU5OTdizszN M3TKXXNCVkeHUh?=
SW684 NEf2NHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LLZmlEPTB;MT65OlA6QSEQvF2= NVn5W4NTW0GQR1XS
TE-8 NEXpSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;DbllIUUN3ME2yMlA2PTV7IN88US=> NU[5UJkzW0GQR1XS
SK-N-DZ NFrSN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXRTWM2OD1{LkGzNlc1KM7:TR?= MUHTRW5ITVJ?
EVSA-T MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vxUmlEPTB;Mj6xO|MyPSEQvF2= MXXTRW5ITVJ?
KASUMI-1 NXH1U3dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDwSYlqUUN3ME2yMlE5QDF3IN88US=> Mnq3V2FPT0WU
NKM-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwMkW0O|Ih|ryP M3PwdXNCVkeHUh?=
CAL-148 M2rMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrjR5JKUUN3ME2yMlM{PjF2IN88US=> NG\TRotUSU6JRWK=
NCI-H64 Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIiwWHBKSzVyPUKuN|QzOzJizszN NHOzTGNUSU6JRWK=
KNS-81-FD NHzaeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJwM{[2NkDPxE1? MXHTRW5ITVJ?
KM12 NXTwTYVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJwNEC4N|kh|ryP M3vH[nNCVkeHUh?=
SW954 M4fSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XxWWlEPTB;Mj60O|c4QSEQvF2= M2S0R3NCVkeHUh?=
NCI-H1395 MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJwNUK2OFUh|ryP NX3qOotoW0GQR1XS
DJM-1 NFu0W|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L3WWlEPTB;Mj62NFY{KM7:TR?= MWXTRW5ITVJ?
COLO-668 NGexdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJwOEK2PVUh|ryP NWH3[mlOW0GQR1XS
NCI-H1436 M1TWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fNOmlEPTB;Mj64OVYyPSEQvF2= Mlm5V2FPT0WU
LB2241-RCC MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwOE[4N|kh|ryP MWDTRW5ITVJ?
GT3TKB NXrvUJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;nTWM2OD1{Lki5NFU2KM7:TR?= MoewV2FPT0WU
COLO-824 MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJwOEm3Olgh|ryP M2HafnNCVkeHUh?=
ES1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHLVJF1UUN3ME2yMlg6QDd7IN88US=> NHLOdGRUSU6JRWK=
LB771-HNC M{jhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrUeoJKSzVyPUKuPVA6PDZizszN MWDTRW5ITVJ?
GI-ME-N NF34Zm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HG[WlEPTB;Mz6wNFkxPCEQvF2= MorxV2FPT0WU
NALM-6 M{HiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPZTWM2OD1|LkCwPVM{KM7:TR?= NEizZ4hUSU6JRWK=
LU-134-A NYC0NGJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTNwMEW0NlUh|ryP M3WwO3NCVkeHUh?=
DMS-153 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNwMEW4NlQh|ryP MkT2V2FPT0WU
MZ1-PC NFO2OWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTNwMEmwO|gh|ryP M4XOeXNCVkeHUh?=
NCI-H1155 NGDDRnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jUVWlEPTB;Mz6xNVYyKM7:TR?= NYmxS4V3W0GQR1XS
CAS-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonwTWM2OD1|LkGzO|A4KM7:TR?= M3HmPHNCVkeHUh?=
D-502MG M2j6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XmVWlEPTB;Mz6xOFM6KM7:TR?= NILiR5VUSU6JRWK=
NCI-H2141 M1PzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTNwMUe0OVIh|ryP M4XSd3NCVkeHUh?=
NB6 NVLjV4l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[5O2lEPTB;Mz6xPFI2QSEQvF2= NG[1UWxUSU6JRWK=
NCCIT MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3hRWVKSzVyPUOuNlE5ODlizszN NGnobXBUSU6JRWK=
NB69 NHXTOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3UOGNKSzVyPUOuN|E5QTFizszN M3XjWnNCVkeHUh?=
JVM-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fE[2lEPTB;Mz6zOlQ{OyEQvF2= M17yOXNCVkeHUh?=
K052 NHHHWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHSTWM2OD1|LkO3PVY5KM7:TR?= NGHVOmRUSU6JRWK=
HCC2157 Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjSTWM2OD1|LkWzNlI5KM7:TR?= M3SwXnNCVkeHUh?=
KMOE-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HzVmlEPTB;Mz61OFI1OiEQvF2= Mn;NV2FPT0WU
SF268 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NICzSoVKSzVyPUOuO|E2PTRizszN NUjvZoRtW0GQR1XS
CHP-126 NGr2Vm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT5fIhKSzVyPUOuO|Y1PThizszN MlrqV2FPT0WU
CP66-MEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\DTWM2OD1|Lke5NFk1KM7:TR?= NHniU29USU6JRWK=
NCI-H69 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfLNI83UUN3ME20MlAyQTN4IN88US=> NEDPW5dUSU6JRWK=
A253 NIK1S4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTRwMEKxNFEh|ryP MkTFV2FPT0WU
NB14 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK3T4FrUUN3ME20MlExPDd7IN88US=> NFy3R2dUSU6JRWK=
NCI-H1694 M4D2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITGcpRKSzVyPUSuNVMyOTJizszN NV;INJB1W0GQR1XS
NCI-H2196 NUnD[5g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjl[YJKSzVyPUSuNVcyPjlizszN MYHTRW5ITVJ?
TE-9 MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTRwMUe1PFIh|ryP MUfTRW5ITVJ?
D-283MED NVHDN3lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPKTWM2OD12LkG4PFQh|ryP MnHpV2FPT0WU
OCI-AML2 M1\IVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLQTWM2OD12LkG5OFg6KM7:TR?= M4roXnNCVkeHUh?=
D-263MG NWftWmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT2VGx6UUN3ME20MlIzQTZzIN88US=> MV\TRW5ITVJ?
MPP-89 MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rCb2lEPTB;ND6yO|MxPCEQvF2= Ml3PV2FPT0WU
LAMA-84 M4DmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnCTWM2OD12LkOwOFIyKM7:TR?= NHfJOI5USU6JRWK=
LB373-MEL-D M1r5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnFTWM2OD12LkO2O|g6KM7:TR?= M1TXOXNCVkeHUh?=
UACC-257 M{\N[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDKfHM4UUN3ME20MlM6PTN2IN88US=> NGD1[lNUSU6JRWK=
MC-CAR MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\KcWlEPTB;ND60N|k6KM7:TR?= M1X1OXNCVkeHUh?=
COLO-320-HSR MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTRwNES0Nlch|ryP NVn6dZNjW0GQR1XS
P30-OHK NIL2V29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID1ZWdKSzVyPUSuOlY2QDFizszN M3y5fXNCVkeHUh?=
UACC-812 NFSyPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT3fndKSzVyPUSuOlkyPjFizszN MU\TRW5ITVJ?
CTB-1 NEDhNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjh[ZFKSzVyPUSuO|E2PTVizszN NWnRWJdmW0GQR1XS
ALL-PO MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;kRmlEPTB;ND64OFA4PyEQvF2= MXLTRW5ITVJ?
SK-MEL-2 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfENYhjUUN3ME20Mlg3QTV3IN88US=> MnnIV2FPT0WU
TC-YIK MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\LTWM2OD12Lkm3PVQzKM7:TR?= NXy5UmJIW0GQR1XS
NCI-H1882 NVzPNmx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTVwMEKwNFEh|ryP NYfMVHEyW0GQR1XS
MHH-CALL-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDMTWM2OD13LkC1NFQzKM7:TR?= MUDTRW5ITVJ?
U-87-MG NF7wXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M164bmlEPTB;NT6wPVQ3PiEQvF2= MlTZV2FPT0WU
NCI-H1092 M4DI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTVwMk[1OVUh|ryP NEXOdnJUSU6JRWK=
TE-441-T NYizbJR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7DTWM2OD13LkK3PFIh|ryP MojrV2FPT0WU
SK-MEL-1 MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PzdWlEPTB;NT6yPVA1PCEQvF2= NHrOWINUSU6JRWK=
EW-22 M3;Gbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG2TWM2OD13LkK5OFY3KM7:TR?= NI[5ZWpUSU6JRWK=
MZ7-mel M3TZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TSS2lEPTB;NT60NFY6OSEQvF2= Mkj6V2FPT0WU
LP-1 Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjXNmg5UUN3ME21MlQyOjlzIN88US=> NXn3N2NMW0GQR1XS
NCI-SNU-16 NUfDO4R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLPTWM2OD13Lk[0NFc1KM7:TR?= M2m1NHNCVkeHUh?=
LU-65 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DhPWlEPTB;NT63OlM4OyEQvF2= NWDENVV{W0GQR1XS
CW-2 NIH4NmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPRU|ZKSzVyPUWuPFU6PTlizszN Mnm3V2FPT0WU
WSU-NHL NHqxc|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTVwOUWxO|Qh|ryP MnL3V2FPT0WU
IST-MES1 M4W0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\pOJhPUUN3ME21Mlk2PDR|IN88US=> MVvTRW5ITVJ?
U-266 NVm1T3VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHhPZdEUUN3ME21Mlk5OjB{IN88US=> M4CxOHNCVkeHUh?=
TALL-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTZwMUS2PFgh|ryP MlvPV2FPT0WU
Calu-6 NEfETZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTZwMUWzNVYh|ryP NV7EeJlXW0GQR1XS
MMAC-SF MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfQSodDUUN3ME22MlE5PTV4IN88US=> NE\wPG5USU6JRWK=
NCI-H82 NWPlNpkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnDTWM2OD14LkKwOFg6KM7:TR?= NUD2U5dsW0GQR1XS
RS4-11 NWWzOVRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfQ[IdZUUN3ME22MlI2QDl5IN88US=> MkKyV2FPT0WU
SNU-C2B MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe5bnNYUUN3ME22MlQxQTZ7IN88US=> NIXZfVZUSU6JRWK=
BOKU MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfpSHVKSzVyPU[uOFc2QTdizszN Mlm0V2FPT0WU
C8166 M{DNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInMPWxKSzVyPU[uOVU6OTJizszN MnnwV2FPT0WU
D-247MG M2PqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\VWmlEPTB;Nz6wOFM1PyEQvF2= NEjlXWlUSU6JRWK=
EW-18 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M335[GlEPTB;Nz6wO|I6OiEQvF2= MWPTRW5ITVJ?
KG-1 MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfscIpKSzVyPUeuOlI4OzhizszN NVS1NlVHW0GQR1XS
REH MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTdwNkixNFkh|ryP MmfjV2FPT0WU
U-698-M M4XWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLYTWM2OD15Lki0N|E2KM7:TR?= M4HZfXNCVkeHUh?=
KP-N-RT-BM-1 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTdwOUOwNlkh|ryP M1nwUXNCVkeHUh?=
MS-1 NYLJZ3FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\NTWM2OD15Lkm2NFQyKM7:TR?= NHW3SWZUSU6JRWK=
SNU-C1 Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f0UWlEPTB;Nz65PFE6OiEQvF2= NVnuRWdHW0GQR1XS
SK-MM-2 MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi5UnJ[UUN3ME24MlI3ODZ3IN88US=> NUjoTmdoW0GQR1XS
LAN-6 NXy3bZdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULuc5RMUUN3ME24MlMxODBzIN88US=> MoSxV2FPT0WU
NEC8 MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRThwM{C2PVEh|ryP Mke0V2FPT0WU
NCI-H1770 MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7TTWM2OD16LkO4NFAzKM7:TR?= MlfVV2FPT0WU
D-336MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXqOndKSzVyPUiuOFAyOTZizszN NVTpdINNW0GQR1XS
COLO-829 MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvhdHBoUUN3ME24MlQ5QDd7IN88US=> NUTpeYx5W0GQR1XS
LS-513 NGH2Oo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXMTWM2OD16LkW5OVk6KM7:TR?= NF33e5lUSU6JRWK=
YT MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nzN2lEPTB;OD62NlQzPyEQvF2= NUL1THYyW0GQR1XS
EW-24 NXTmXmI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NImzR|JKSzVyPUiuO|Y2PCEQvF2= MXzTRW5ITVJ?
IST-SL1 NX\pWZpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vsZ2lEPTB;OD64OlU1OyEQvF2= M2TlfXNCVkeHUh?=
CA46 M{\CW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULxWZhzUUN3ME24Mlk2ODl6IN88US=> NGLHcJJUSU6JRWK=
NCI-H1838 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRThwOUi2NFIh|ryP MVLTRW5ITVJ?
NCI-H719 MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTlwMkWyO|kh|ryP MYHTRW5ITVJ?
HCE-T M{n6fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rwOWlEPTB;OT6zNFg2OSEQvF2= MkHNV2FPT0WU
A498 M3:1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqwWHFKSzVyPUmuN|YyOjRizszN MlX0V2FPT0WU
LB831-BLC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\IOmlEPTB;OT63OlUzOSEQvF2= MnTwV2FPT0WU
SKM-1 MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHDTWM2OD17Lki1PVY{KM7:TR?= MnP3V2FPT0WU
THP-1 NXiyTXVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3WTWM2OD17Lkm2PVE5KM7:TR?= NV3uSpB4W0GQR1XS
SHP-77 NUDBfI5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFyLkSwO{DPxE1? MV;TRW5ITVJ?
EW-3 NVjMOmU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3juUmlEPTB;MUCuOlI5QSEQvF2= MnTqV2FPT0WU
KY821 M1rOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfxVotKSzVyPUGwMlc3OyEQvF2= MmC1V2FPT0WU
NCI-SNU-1 NVrsbYVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXSTWM2OD1zMT6wNlE4KM7:TR?= MUPTRW5ITVJ?
HCC2218 NVXCe5RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWCxV|doUUN3ME2xNU4{QTh4IN88US=> NFfob21USU6JRWK=
IM-9 M1Hi[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofpTWM2OD1zMT61NVA3KM7:TR?= NUS4bXptW0GQR1XS
NCI-H889 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrJWmZSUUN3ME2xNU42OzF|IN88US=> NVXWSHdlW0GQR1XS
HDLM-2 M3K2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInpem1KSzVyPUGyMlQyPTlizszN NFXpVI9USU6JRWK=
LB2518-MEL MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXtTWM2OD1zMj62PFE2KM7:TR?= MWLTRW5ITVJ?
NCI-H23 Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF|LkK0NlUh|ryP NEPnWXNUSU6JRWK=
NB17 MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O5ZmlEPTB;MUOuOFU4QSEQvF2= MUPTRW5ITVJ?
NCI-H322M MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF2LkSwOlgh|ryP M3fKPHNCVkeHUh?=
SUP-T1 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITZN45KSzVyPUG0MlQyOyEQvF2= M{PLeXNCVkeHUh?=
ES3 NEDaT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rtRWlEPTB;MUWuNFcxOyEQvF2= Mlr2V2FPT0WU
ES5 NUTBW2NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTF3LkC3PFch|ryP NHXOcmpUSU6JRWK=
NCI-H1650 M3;EOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DKVWlEPTB;MUWuOFk4QSEQvF2= NF;lXWRUSU6JRWK=
NCI-H226 M3j5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF3Lki3Olgh|ryP NUH0d3JpW0GQR1XS
COR-L88 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF4LkOxOEDPxE1? M2TqVnNCVkeHUh?=
SCC-15 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILi[ZRKSzVyPUG2MlM5PjlizszN MVnTRW5ITVJ?
GOTO MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTVTWM2OD1zNj60O|k{KM7:TR?= NGjXSY1USU6JRWK=
SIMA MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[wTWM2OD1zNj60PFAzKM7:TR?= MlzKV2FPT0WU
NCI-H1299 Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXON4RKSzVyPUG3MlE2QTFizszN MoP1V2FPT0WU
NCI-H1581 M3\VSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm3U|RKSzVyPUG3MlQzOTlizszN M3[4O3NCVkeHUh?=
MHH-NB-11 NEP2flhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnpSlFKUUN3ME2xO{46Pjh|IN88US=> M2D0dXNCVkeHUh?=
MFM-223 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXmyfo9GUUN3ME2xPE4xPTN6IN88US=> NG\wPFVUSU6JRWK=
ES7 Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjhfGVKSzVyPUG4MlU1OzFizszN MYHTRW5ITVJ?
JVM-3 NYWwO2xMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXXe4NrUUN3ME2xPE44OTdizszN NG\DTWFUSU6JRWK=
RL NGHXbYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTJTWM2OD1{MD6zPFgh|ryP MWXTRW5ITVJ?
EC-GI-10 MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnKTWM2OD1{MT6yNFQyKM7:TR?= NG[yUnRUSU6JRWK=
LNCaP-Clone-FGC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJzLk[3Olgh|ryP Mn;4V2FPT0WU
IMR-5 NVLYUIs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL3OY5KSzVyPUKxMlg1QTRizszN MnjOV2FPT0WU
KP-N-YS MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV72XlM1UUN3ME2yNU45PzVizszN M13CPHNCVkeHUh?=
Mo-T NX[2VlBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ixTmlEPTB;MkKuNlE5PSEQvF2= NH6wOoNUSU6JRWK=
NCI-H128 NUnOfm5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjzeGFYUUN3ME2yN{42QDV|IN88US=> Mmm4V2FPT0WU
RH-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;BW2lEPTB;MkOuO|g3PiEQvF2= MXXTRW5ITVJ?
NCI-H2171 NEXRWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPBTWM2OD1{ND6yOFg2KM7:TR?= NXPLd3V3W0GQR1XS
RPMI-8866 M4TQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XTeWlEPTB;Mk[uO|QzKM7:TR?= MXzTRW5ITVJ?
SK-N-FI MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX4SpBKSzVyPUK3MlM5OTFizszN M2nTeHNCVkeHUh?=
LOXIMVI M{DjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJ5LkiwOVEh|ryP M3jwPHNCVkeHUh?=
P31-FUJ NWXucFhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzSXmVKSzVyPUOxMlU{PzRizszN NVrT[Vl{W0GQR1XS
KMS-12-PE M3vWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3NSHNVUUN3ME20PU42OzB{IN88US=> NV\PfIlWW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% CMC/0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

カスタマーフィードバック (12)


Click to enlarge
Rating
Source Nat Genet, 2014, 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell, 2011, 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res, 2012, 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source Autophagy, 2015, 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck
Method Cell imaging
Cell Lines H4-LC3-GFP cells
Concentrations 200 nM
Incubation Time 24 h
Results Consistent with inhibition of autophagy, the levels of LC3-II were lower and the levels of SQSTM1/p62 were higher in this USP18 knockdown cell line compared to that of control under basal conditions as well as the induced condition after the treatment with rapamycin.

Click to enlarge
Rating
Source Cell Rep, 2015, 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 250 nM
Incubation Time 24 h
Results Rapamycin virtually abolishes stimulation by Rheb of phospho-S6 kinase and phospho-4EBP1 but has negligible effects on phospho-eIF2a (A). In contrast to phosphorylation of eIF2a, which is not mediated by mTORC1, phosphorylation of other elongation factors does involve mTORC1. Thus, rapamycin prevents phosphorylation of eIF4G and eIF4B, targets of S6K, but not eIF2a (B). By contrast, rapamycin, as expected, abolishes phospho-S6 kinase but fails to influence phospho-eIF2a, phospho-Erk or phospho-Akt (C).

Click to enlarge
Rating
Source Biochem Pharmacol, 2015, 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck
Method Immunofluorescence
Cell Lines RAW264.7 cells
Concentrations 10 uM
Incubation Time 16 h
Results It has been reported that autophagy can directly regulate inflammatory responses. To confirm this phenomenon, we pre-treated RAW264.7 cells with 3-MA (an autophagy inhibitor by blocking the class III PI3Ks) or rapamycin (an autophagy inducer by targeting the negative regulators against autophagy as mammalian target of rapamycin (mTOR)), followed by addition of LPS. LPS-induced punctate LC3 was markedly reduced and enhanced in the presence of 3-MA and rapamycin, respectively.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source J Lipid Res, 2011, 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochim Biophys Acta, 2013, 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis, 2013, 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2011, Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Click to enlarge
Rating
Source 2013, Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

文献中の引用 (55)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin (Compound C)

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ